MODERNA INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
MODERNA INC. - More news...
MODERNA INC. - More news...
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
- Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
- Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
- Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
- Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
- Moderna to Present at Upcoming Conferences in November 2023
- Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
- Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
- Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
- CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
- Moderna Named a Top Employer by Science for Ninth Consecutive Year
- Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
- Moderna to Host Second Digital Investor Event on November 8th, 2023
- Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
- Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
- Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
- EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
- Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
- Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
- Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
- Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
- Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
- Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
- Moderna to Host Investor Event - R&D Day and Business Updates
- Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
- Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
- Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
- Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
- Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
- Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
